STEEPLE bleeding criteria: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
m (Bot: Removing from Primary care) |
||
(16 intermediate revisions by 2 users not shown) | |||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{ | {{Bleeding}} | ||
{{CMG}} | {{CMG}} | ||
==Steeple Bleeding Criteria (DO NOT EDIT)<ref name="pmid19171853">{{cite journal| author=Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J et al.|title=Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial. | journal=Circulation | year= 2009 | volume= 119 | issue= 5 | pages= 680-6 | pmid=19171853 |doi=10.1161/CIRCULATIONAHA.108.803528 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19171853 }} </ref>== | |||
{{cquote| | {{cquote| | ||
Safety and Efficacy Of [[Enoxaparin]] In [[Percutaneous Coronary Intervention]] Patients: An International Randomized Evaluation | |||
'''Major Bleeding''' | |||
* Fatal [[bleeding]] | |||
* Retroperitoneal, intracranial, or [[intraocular bleeding]] | |||
* Bleeding that causes hemodynamic compromise requiring specific treatment | |||
* Bleeding that requires intervention (surgical or endoscopic) or decompression of a closed space to stop or control the event | |||
* Clinically overt bleeding, requiring any transfusion of ≥1 U PRBC or whole blood | |||
* Clinically overt bleeding, causing a decrease in hemoglobin of ≥3 g/dL (or, if hemoglobin level is not available, a decrease in hematocrit of ≥10%) | |||
'''Minor''' | |||
*Gross [[hematuria]] not associated with [[trauma]] (eg, from instrumentation) | |||
*[[Epistaxis]] that is prolonged, is repeated, or requires plugging or intervention | |||
*Gastrointestinal hemorrhage | |||
* [[Hemoptysis]] | |||
* [[Subconjunctival hemorrhage]] | |||
* [[Hematoma]] >5 cm or leading to prolonged or new hospitalization | |||
*Clinically overt bleeding, causing a decrease in hemoglobin of 2 to 3 g/dL | |||
*Uncontrolled bleeding requiring protamine sulfate administration}} | |||
* | |||
Gross hematuria not associated with trauma (eg, from instrumentation) | |||
Epistaxis that is prolonged, is repeated, or requires plugging or intervention | |||
Gastrointestinal hemorrhage | |||
Hemoptysis | |||
Subconjunctival hemorrhage | |||
Hematoma >5 cm or leading to prolonged or new hospitalization | |||
Clinically overt bleeding, causing a decrease in hemoglobin of 2 to 3 g/dL | |||
Uncontrolled bleeding requiring protamine sulfate administration | |||
== References == | == References == | ||
{{Reflist}} | {{Reflist}} | ||
{{WH}} | |||
{{WS}} | |||
[[Category:Medical emergencies]] | [[Category:Medical emergencies]] | ||
[[Category:Blood]] | [[Category:Blood]] | ||
[[Category:Hematology]] | [[Category:Hematology]] | ||
Latest revision as of 00:17, 30 July 2020
Bleeding Microchapters |
Treatment |
---|
Reversal of Anticoagulation and Antiplatelet in Active Bleed |
Perioperative Bleeding |
STEEPLE bleeding criteria On the Web |
American Roentgen Ray Society Images of STEEPLE bleeding criteria |
Risk calculators and risk factors for STEEPLE bleeding criteria |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Steeple Bleeding Criteria (DO NOT EDIT)[1]
“ |
Safety and Efficacy Of Enoxaparin In Percutaneous Coronary Intervention Patients: An International Randomized Evaluation Major Bleeding
Minor
|
” |
References
- ↑ Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J; et al. (2009). "Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial". Circulation. 119 (5): 680–6. doi:10.1161/CIRCULATIONAHA.108.803528. PMID 19171853.